Shan Xin
Postdoctoral AssociateAbout
Research
Publications
2026
AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling
Liu C, Hu C, Cheng J, Xin D, Jin S, Tian W, Li S, Jin Y, Liu Y, Wu W, Hao S, Ren H, Dai X, Liu L, Ruan J, Fang W, Bao X, Xin S, Zhao P. AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling. Journal For ImmunoTherapy Of Cancer 2026, 14: e013305. PMID: 41807033, PMCID: PMC12983827, DOI: 10.1136/jitc-2025-013305.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsICI responseImmune checkpoint inhibitor efficacyIFN-gICI-treated patientsFerroptosis sensitivityTumor microenvironment remodelingIn vivoLipid remodelingSusceptible to ferroptosisCheckpoint inhibitorsFerroptosis-related genesImmunotherapy efficacyOverall survivalImmune activationTumor eliminationTumor cellsPotential of ferroptosisMicroenvironment remodelingImmune regulationAntitumor mechanismTranscription factor IRF1Gene signatureSingle-cell RNA sequencing datasetsTumorRational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators.
Zhang F, Dong C, Chow R, Xin S, He E, Feng Y, Zhu L, Mirza D, Tian X, Yang L, Zhou L, Ling X, Han Q, Fan R, Chen S, Wang G. Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators. Cancer Discovery 2026 PMID: 41747251, DOI: 10.1158/2159-8290.cd-25-0545.Peer-Reviewed Original ResearchTherapy combinationsTumor microenvironmentAntigen presentationTCR-T cell therapyAnti-tumor immunityAnti-tumor responsesSolid tumors in vivoHostile tumor microenvironmentT cell proliferationT cell activationTumor microenvironment modulationTumors in vivoCAR-TCancer immunotherapyTumor infiltrationMetastatic tumorsTCR-TTherapeutic combinationsSolid tumorsCell therapyCo-StimulationTumorMicroenvironment modulationTNFSF9Activation of genesHigh-Resolution Spatial Multi-Omics Enables Prognostic Scoring in Intrahepatic Cholangiocarcinoma
Jin Y, Mei J, Cheng J, Liu Q, Hong L, Gao L, Xie L, Sun X, Tang Y, Xin S, Shi Y, Dai X, Tong Z, Zhang H, Fu W, Chen J, Ruan J, Fang W, Yun J, Deng H, Wei W, Lin B, Zhao P, Bao X. High-Resolution Spatial Multi-Omics Enables Prognostic Scoring in Intrahepatic Cholangiocarcinoma. Molecular Therapy 2026 PMID: 41709577, DOI: 10.1016/j.ymthe.2026.02.029.Peer-Reviewed Original ResearchIntrahepatic cholangiocarcinomaRisk stratificationScoring systemImmune checkpoint inhibitorsDismal clinical outcomeMulti-omics characterizationCheckpoint inhibitorsPrognostic scoreHepatic malignanciesIntertumoral heterogeneityTumor microenvironmentTargeted therapyMulti-omics investigationsMultiplex immunofluorescenceImaging Mass CytometryTraining cohortClinical outcomesTherapeutic advancesPrognostic powerTherapeutic decisionsPrognostic toolSingle-cell RNA sequencingGlobal incidenceMass cytometryTreatment optimization
2025
Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
Zhang H, Hong L, Dong Z, Xin S, Lin B, Cheng J, Tian W, Li B, Wang J, Liu X, Liu C, Jin Y, Feng Y, Su G, Sun X, Liu Q, Dai X, Gao Y, Tong Z, Liu L, Zhu X, Zheng Y, Zhao P, Guo T, Fang W, Bao X. Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response. Cell Discovery 2025, 11: 60. PMID: 40593467, PMCID: PMC12219098, DOI: 10.1038/s41421-025-00811-2.Peer-Reviewed Original ResearchResident tissue macrophagesColorectal cancerImmunotherapy responseTumor microenvironmentNon-respondersCD4+ T cellsResistance to immunotherapyMetastatic colorectal cancerColorectal cancer microenvironmentMicrosatellite stabilityMHC-II expressionMicrosatellite instabilityT cell nicheCancer-associated fibroblastsMetastatic CRCImmunotherapy respondersT cellsImaging Mass CytometryAntigen presentationImmunotherapyCancer microenvironmentSingle-cell RNA sequencingMHC-IITissue macrophagesMass cytometrySpatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis
Gao Y, Li B, Jin Y, Cheng J, Tian W, Ying L, Hong L, Xin S, Lin B, Liu C, Sun X, Zhang J, Zhang H, Xie J, Deng X, Dai X, Liu L, Zheng Y, Zhao P, Yu G, Fang W, Bao X. Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis. Oncogene 2025, 44: 2268-2282. PMID: 40234722, DOI: 10.1038/s41388-025-03388-y.Peer-Reviewed Original ResearchConceptsLung metastasesTumor microenvironmentBreast cancerImaging Mass CytometryHLA-DR+Primary BCTME componentsEndothelial cellsTumour microenvironment of BCEpithelial cellsPaired lung metastasesExhausted T cellsTriple-negative subtypeMultiplex immunofluorescence analysisPrimary breast cancerAnti-angiogenic therapyDevelopment of therapeutic optionsFormalin-fixed paraffin-embedded (FFPEParaffin-embedded (FFPELung-specific metastasisOligo-metastasisMetastatic tumorsSurgical specimensMultiplex immunofluorescenceT cellsCas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
Tang K, Zhou L, Tian X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim H, Luo Z, Xin S, Lin S, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam S, Chow R, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth C, Liu C, Fan R, Dong M, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nature Biomedical Engineering 2025, 9: 1290-1308. PMID: 40114032, PMCID: PMC12360953, DOI: 10.1038/s41551-025-01371-2.Peer-Reviewed Original ResearchKnock-In MiceBone marrow-derived dendritic cellsCD8+ T cellsNon-viral delivery vehiclesAdeno-associated virusDisease modelsCD4+Dendritic cellsC57BL/6 backgroundT cellsConstitutive expressionB cellsLipid nanoparticlesEx vivoGenome editingMiceMultiplex genome engineeringROSA26 locusGene interaction networksMultiplex genome editingLiver tissueTargeted genome editingDiseaseDelivery vehiclesCRISPR RNAExploring FAM13A-N-Myc interactions to uncover potential targets in MYCN-amplified neuroblastoma: a study of protein interactions and molecular dynamics simulations
Yin H, Liu T, Wu D, Li X, Li G, Song W, Wang X, Xin S, Liu Y, Pan J. Exploring FAM13A-N-Myc interactions to uncover potential targets in MYCN-amplified neuroblastoma: a study of protein interactions and molecular dynamics simulations. BMC Cancer 2025, 25: 470. PMID: 40087586, PMCID: PMC11907995, DOI: 10.1186/s12885-025-13903-9.Peer-Reviewed Original ResearchConceptsN-mycTranscriptome dataProtein structureStudy of protein interactionsProtein-protein dockingMolecular dynamics modeling techniquesProliferation of NB cellsMolecular dynamics simulationsMYCN-amplified neuroblastomaProtein interactionsProtein stabilityCell cycleFAM13AMYCN-amplified NBCell function experimentsAlphaFoldDynamics simulationsNB cellsCell proliferationClinical samplesFunctional experimentsTherapeutic targetProteinCellsGROMACSSpatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma
Hong L, Mei J, Sun X, Wu Y, Dong Z, Jin Y, Gao L, Cheng J, Tian W, Liu C, Li B, Hu P, Liu L, Xin S, Dai X, Zhao P, Guo R, Chen M, Yun J, Lin B, Wei W, Fang W, Bao X. Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma. Hepatology 2025, 83: 57-74. PMID: 39999448, DOI: 10.1097/hep.0000000000001283.Peer-Reviewed Original ResearchConceptsPrognosis of patientsIntrahepatic cholangiocarcinomaTumor microenvironmentTherapeutic responseCD8+ T cellsFeatures associated with prognosisTherapeutic response of patientsDevelopment of personalized treatment strategiesPoor patient survivalResponse of patientsPotential therapeutic optionPersonalized treatment strategiesAntitumor immunityPatient survivalMultiplex immunofluorescenceT cellsTherapeutic optionsImaging Mass CytometryTumor samplesTreatment strategiesSingle-cell RNA sequencingPrognosisMass cytometryPatientsTumorAuthor Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Author Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 43: 2068-2068. PMID: 39901026, DOI: 10.1038/s41587-025-02576-1.Peer-Reviewed Original ResearchMultiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 43: 2054-2067. PMID: 39820813, DOI: 10.1038/s41587-024-02535-2.Peer-Reviewed Original ResearchAdeno-associated virusTumor microenvironmentImmunosuppressive genesAntitumor efficacyCD8+ T cell infiltrationIn vivo antitumor efficacyCombinatorial cancer immunotherapyImmunosuppressive tumor microenvironmentSyngeneic tumor modelsT cell infiltrationTumor microenvironment remodelingMulti-agent combinationsMultiple tumor typesAntitumor immunityCombinatorial immunotherapyOptimal immunotherapyCancer immunotherapyGene alterationsTumor typesTumor modelReduced neutrophilLiver toxicityShRNA treatmentWhole-transcriptome profilingImmunotherapy
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email